Alliance Pharma PLC

Alliance Pharma PLC

  • Price (EUR)0.535
  • Today's Change0.293 / 121.07%
  • Shares traded6.00k
  • 1 Year change-54.66%
  • Beta--
Data delayed at least 15 minutes, as of Nov 29 2022.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Alliance Pharma plc is a United Kingdom-based holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's asset portfolio focused on two areas: Consumer Healthcare brands and Prescription Medicines. It holds marketing rights to approximately 80 consumer healthcare brands and Prescription Medicines, which are sold worldwide in approximately 100 countries. Its products include Aloclair, Alliance Calcium Syrup, Aiweidi, Biodermatin, Biotaches, Changmin, Decapional, Dermachronic, Dermacide, Dervida, Effadiane, Fazol, Flammacerium, Gen-Ongles, Irenat, Malunjunshe, MolluDab, Neostigmine and Nu-Seals and other. The Company’s brands also include Kelo-Cote, Nizoral, Amberen, MacuShield, Vamousse, Hydromol, Forceval, Ashton & Parsons, Anbesol, and Aloclair. Its geographical area includes Europe, Middle East and Africa (EMEA), Asia Pacific and China (APAC) and Americas (AMER).

  • Revenue in GBP (TTM)163.34m
  • Net income in GBP12.18m
  • Incorporated2001
  • Employees250.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
APH:LSE since
Mitchell-Vance Laboratories LLCDeal completed21 Mar 202221 Mar 2022Deal completed-56.99%19.40m
Data delayed at least 20 minutes, as of Nov 30 2022 12:27 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.